Antiulcerogenic activity of zinc acexamate in different experimental models.
The antiulcerogenic activity of zinc acexamate (ZAC; Laboratorios Viñas, S.A.) has been tested in several models of gastric injury induced by acid hypersecretion, prostaglandin blockade and disruption of the gastric barrier. Lowest doses which have demonstrated to significantly prevent gastric damage ranged from 10 to 100 mg/kg depending on the experimental model used. The benefit obtained with this compound was always dose-dependent. These findings would support the hypothesis that ZAC acts by a complex inhibition of several of the mechanisms involved in the development of peptic diseases.
Escolar
G
G
Departamento de Farmacología, Laboratorios Viñas, S.A., Barcelona, Spain.
Camarasa
J
J
Navarro
C
C
Vernetta
C
C
Bulbena
O
O
D000614:Aminocaproates / Q000627:therapeutic use*; D015119:Aminocaproic Acid / Q000627:therapeutic use*; D000818:Animals; D001647:Bile Acids and Salts; D004195:Disease Models, Animal; D005260:Female; D008297:Male; D051379:Mice; D010653:Phenylbutazone; D011239:Prednisolone; D051381:Rats; D011919:Rats, Inbred Strains; D013276:Stomach Ulcer / Q000209:etiology / Q000517:prevention & control*; D013312:Stress, Physiological / Q000150:complications
D000614:Aminocaproates; D001647:Bile Acids and Salts; C018802:6-acetylaminocaproic acid; D011239:Prednisolone; D010653:Phenylbutazone; D015119:Aminocaproic Acid